Results 241 to 250 of about 274,716 (345)
Microglial lipid metabolic dysfunction drives neurodegeneration in glaucoma. We found loss of LRP1 causes lipid accumulation and inflammation. We developed alpinetin‐loaded nanoparticles (AlpNPs) that bind LRP1, activate the PPARγ‐LXRα‐ABCA1 pathway to restore lipid homeostasis, promote an anti‐inflammatory phenotype, and protect retinal ganglion cells,
Miao Wei +8 more
wiley +1 more source
Constipation and Parkinson disease: A 2-sample bidirectional Mendelian randomization analysis. [PDF]
Li H +5 more
europepmc +1 more source
This study demonstrates that polyC‐RNA‐binding protein 1 (PCBP1) in ventral hippocampal astrocytes modulates depressive‐like behaviors by regulating glutathione peroxidase 4‐mediated ferroptosis and synaptic glutamatergic transmission. PCBP1 overexpression intervention in the chronic unpredictable mild stress model rescues behavioral deficits ...
Jinyu Zhang +15 more
wiley +1 more source
Human participants with early‐ or chronic‐stage tendinopathy and healthy controls are investigated using ultrasound Doppler, 3T and 7T MRI, and tendon biopsies. Tendon swelling and hyperperfusion are evident early, while vascular growth and extracellular matrix changes are most pronounced in chronic tendinopathy. Early intervention may provide superior
Max F. R. Merkel +11 more
wiley +1 more source
Correlates of Loneliness in Parkinson Disease During the COVID-19 Pandemic: A Longitudinal Study. [PDF]
de Figueiredo JM +5 more
europepmc +1 more source
This study reveals that the deubiquitinase USP11 stabilizes PGAM5, triggering neurotoxic astrocyte transformation after intracerebral hemorrhage. PGAM5 promotes mPTP opening and Drp1 dephosphorylation, synergistically amplifying mtDNA leakage into the cytosol and leading to cGAS–STING hyperactivation.
Jiaqing He +10 more
wiley +1 more source
Editorial: Exercise and neuroplasticity in Parkinson disease. [PDF]
Hirsch MA, Dalgas U, van Wegen EEH.
europepmc +1 more source
Nanomedicines Against Mitochondrial Dysfunction‐Induced Metabolic Diseases
Mitochondrial dysfunction is central to metabolic diseases. Nanomedicine offers transformative approaches for restoring function via targeted delivery, responsive release, and multimodal therapy. This review outlines the pathological basis, nanocarrier design, organelle‐specific targeting, recent advances, and future clinical translation challenges ...
Ke Xu +9 more
wiley +1 more source

